Feature|Articles|April 3, 2025

Unpacking the Truth Behind GLP-1 Myths

Experts across healthcare debunk 15 common myths about GLP-1 medications—covering everything from access and cost to lifestyle changes and long-term effectiveness—to help patients and providers separate hype from reality.

Glucagon-like peptide 1 (GLP-1) receptor agonists have transformed the treatment of type 2 diabetes and obesity since the FDA approval of Byetta (exenatide) for type 2 in 2005. However, their growing popularity has also created widespread misconceptions.